UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Chronic graft versus host disease burden and late transplant complications are lower following adult double cord blood versus matched unrelated donor peripheral blood transplantation

Bone marrow transplantation (Basingstoke), 2016-12, Vol.51 (12), p.1588-1593

2016

Volltextzugriff (PDF)

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia

Leukemia, 2012-05, Vol.26 (5), p.893-901

2012

Volltextzugriff (PDF)

Adjusting DLCO for Hb and its effects on the Hematopoietic Cell Transplantation-specific Comorbidity Index

Bone marrow transplantation (Basingstoke), 2013-09, Vol.48 (9), p.1253-1256

2013

Volltextzugriff (PDF)

Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation

Bone marrow transplantation (Basingstoke), 2007-12, Vol.40 (11), p.1027-1032

2007

Volltextzugriff (PDF)

Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning

Bone marrow transplantation (Basingstoke), 2006-02, Vol.37 (3), p.307-310

2006

Volltextzugriff (PDF)

P570: REAL‐WORLD EFFICACY OUTCOMES OF VENETOCLAX PLUS AZACITIDINE VS INTENSIVE CHEMOTHERAPY FOR INDUCTION THERAPY IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA

HemaSphere, 2022-06, Vol.6, p.469-470

2022

Volltextzugriff (PDF)

S166: MAGROLIMAB IN COMBINATION WITH AZACITIDINE FOR PATIENTS WITH UNTREATED HIGHER‐RISK MYELODYSPLASTIC SYNDROMES (HR MDS): 5F9005 PHASE 1B STUDY RESULTS

HemaSphere, 2022-06, Vol.6, p.67-68

2022

Volltextzugriff (PDF)

P519: TRANSFUSION INDEPENDENCE AMONG NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING VENETOCLAX‐BASED COMBINATIONS VS OTHER THERAPIES: RESULTS FROM THE AML REAL WORLD EVIDENCE (ARC) INITIATIVE

HemaSphere, 2022-06, Vol.6, p.418-419

2022

Volltextzugriff (PDF)

Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials

Haematologica (Roma), 2014-08, Vol.99 (8), p.1277-1284

2014

Volltextzugriff (PDF)

Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia

Haematologica (Roma), 2013-04, Vol.98 (4), p.591-596

2013

Volltextzugriff (PDF)

Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia

Drugs of Today, 2013-07, Vol.49 (7), p.447-456

2013

Volltextzugriff (PDF)

Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia

Drugs of Today, 2013-04, Vol.49 (4), p.261-269

2013

Volltextzugriff (PDF)

Sequential azacitidine and lenalidomide in elderly acute myeloid leukemia: completed results of the phase I study

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.6505-6505

2011

Volltextzugriff (PDF)

Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.8012-8012

2010

Volltextzugriff (PDF)

An early-phase study of azacitidine and lenalidomide for untreated elderly acute myeloid leukemia (AML) patients

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.TPS280-TPS280

2010

Volltextzugriff (PDF)

TNP-470 promotes initial vascular sprouting in xenograft tumors

Molecular cancer therapeutics, 2004-03, Vol.3 (3), p.335-343

2004

Volltextzugriff (PDF)

The Role of Chemistry in Fracture Pattern Development and Opportunities to Advance Interpretations of Geological Materials

Reviews of geophysics (1985), 2019-09, Vol.57 (3), p.1065-1111

2019

Volltextzugriff (PDF)

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

Blood, 2019-01, Vol.133 (1), p.7-17

2019

Volltextzugriff (PDF)

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

The lancet oncology, 2018-02, Vol.19 (2), p.216-228

2018

Volltextzugriff (PDF)

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

Cancer discovery, 2016-10, Vol.6 (10), p.1106-1117

2016

Volltextzugriff (PDF)

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine

Clinical cancer research, 2022-12, Vol.28 (24), p.5272-5279

2022

Volltextzugriff (PDF)

Beyond Survival: The US Food and Drug Administration Confirms Surrogate End Points for Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Intensive Chemotherapy

Journal of clinical oncology, 2022-03, Vol.40 (8), p.811-813

2022

Volltextzugriff (PDF)

Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study

American journal of hematology, 2021-02, Vol.96 (2), p.208-217

2021

Volltextzugriff (PDF)

New directions for emerging therapies in acute myeloid leukemia: the next chapter

Blood cancer journal (New York), 2020-10, Vol.10 (10), p.107-107, Article 107

2020

Volltextzugriff (PDF)

1 – 25 von 99

Suche als RSS-Feed

Aktive Filter

ThemaIsocitrate Dehydrogenase - Genetics

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(92)
Mit Volltextzugriff
(93)

Publikationsform

Artikel
(98)
Berichte
(1)

Sprache

Englisch
(99)

Erscheinungsjahr

n.n

Thema

Science & Technology
(34)
Life Sciences & Biomedicine
(32)
Humans
(29)
Hematology
(21)
Aged
(16)
Oncology
(16)
Female
(14)
Male
(14)
Middle Aged
(12)
Treatment Outcome
(9)
Aged, 80 And Over
(8)
Leukemia, Myeloid, Acute - Drug Therapy
(8)
Prognosis
(7)
Acute Myeloid Leukemia
(6)
Adult
(6)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6)
Chemotherapy
(6)
Leukemia, Myeloid, Acute - Genetics
(6)
Stem Cell Transplantation
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Chronic graft versus host disease burden and late transplant complications are lower following adult double cord blood versus matched unrelated donor peripheral blood transplantation

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia

Adjusting DLCO for Hb and its effects on the Hematopoietic Cell Transplantation-specific Comorbidity Index

Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation

Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning

P570: REAL‐WORLD EFFICACY OUTCOMES OF VENETOCLAX PLUS AZACITIDINE VS INTENSIVE CHEMOTHERAPY FOR INDUCTION THERAPY IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA

S166: MAGROLIMAB IN COMBINATION WITH AZACITIDINE FOR PATIENTS WITH UNTREATED HIGHER‐RISK MYELODYSPLASTIC SYNDROMES (HR MDS): 5F9005 PHASE 1B STUDY RESULTS

P519: TRANSFUSION INDEPENDENCE AMONG NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING VENETOCLAX‐BASED COMBINATIONS VS OTHER THERAPIES: RESULTS FROM THE AML REAL WORLD EVIDENCE (ARC) INITIATIVE

Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials

Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia

Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study

Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia

Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia

Sequential azacitidine and lenalidomide in elderly acute myeloid leukemia: completed results of the phase I study

Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study

An early-phase study of azacitidine and lenalidomide for untreated elderly acute myeloid leukemia (AML) patients

TNP-470 promotes initial vascular sprouting in xenograft tumors

The Role of Chemistry in Fracture Pattern Development and Opportunities to Advance Interpretations of Geological Materials

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine

Beyond Survival: The US Food and Drug Administration Confirms Surrogate End Points for Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Intensive Chemotherapy

Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study

New directions for emerging therapies in acute myeloid leukemia: the next chapter

Aktive Filter

Suchergebnisse filtern